Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Non-small Cell Lung Cancer

NCT02204059 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: hMAb BIWA 4

Sponsor

Boehringer Ingelheim